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There are several reports to demonstrate that rifampicin, a major anti-tuberculosis 
agent, is associated with some adverse renal effects, with a few cases of rifampicin-
induced minimal change disease (MCD). In the present case, a 68-year-old female 
presented with nausea, vomiting, foamy urine, general weakness and edema. She 
had been taking rifampicin for 4 weeks due to pleural tuberculosis. The patient had 
no proteinuria before the anti-tuberculosis agents were started, but urine tests upon 
admission showed heavy proteinuria with a 24-h urinary protein of 9.2 g/day, and 
serum creatinine, albumin, and total cholesterol levels were 1.36 mg/dL, 2.40 g/dL, 
and 283 mg/dL, respectively. MCD was diagnosed, and the patient achieved com-
plete remission after cessation of rifampicin without undergoing steroid therapy.
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INTRODUCTION
Rifampicin is one of the standard drugs used to treat tuberculosis, however, has 
been reported to induce some adverse renal effects.1-10 The most frequent form of 
nephrotoxicity is a syndrome consisting of acute renal failure with pathological 
findings of tubular necrosis, while other forms of nephrotoxicity include interstitial 
nephritis with or without mild glomerular lesions, rapidly progressive glomerulo-
nephritis and light chain proteinuria.2 Rifampicin-associated nephrotic syndrome 
has been published, including cases of rifampicin-induced minimal change disease 
(MCD).4,7,9 Generally, MCD is treated with glucocorticoids,11,12 and rifampicin-in-
duced MCD was treated with a steroid in a previous case.9 Herein, however, we 
report a patient with MCD after rifampicin treatment, which was improved after 
rifampicin cessation without steroid therapy.
CASE REPORT
A 68-year-old female was admitted to the hospital because of a 5-day history of 
left pleuritic chest pain. She had no other relevant medical history except for a ten-
year history of hypertension. On admission, her blood pressure was 146/70 mm 
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Antinuclear antibody and P-anti-neutrophil cytoplasmic an-
tibody (ANCA) and C-ANCA were all negative with nor-
mal serum complement levels.
According to a renal biopsy, MCD was present with fo-
cal thinning of the glomerular basement membrane (Fig. 
1A). Non-sclerotic glomeruli were normocellular without 
mesangial expansion, and the tubules showed minimal atro-
phy and mild focal tubular injury. Additionally, the intersti-
tium was widened by minimal fibrosis, and no depositions 
of immunoglobulins or complement components were ob-
served in the glomeruli. Electron microscopy showed the 
podocyte foot processes to be diffusely effaced (Fig. 1B).
Due to toxic hepatitis, rifampicin and isoniazid were dis-
continued, but ethambutol hydrochloride and pyrazinamide 
were maintained. Moxifloxacin was added after 1 week, 
and isoniazid was added after 2 weeks. The pleural tubercu-
losis was well controlled with isoniazid, ethambutol hydro-
chloride, and moxifloxacin thereafter.
When her diagnosis was confirmed to be MCD, we deter-
mined to use steroid therapy at first. However, she was 
afraid of adverse effects of steroid treatment and asked us to 
observe closely. Moreover, we found out that heavy protein-
uria was developed after using anti-tuberculosis agents. In 
addition, hepatitis also occurred after anti-tuberculosis 
agents started, and then we had to stop rifampicin and isoni-
azid agents. Fortunately, she improved spontaneously with-
out steroid use only after quitting rifampicin. Therefore, we 
observed and followed up continuously. Her nausea, vomit-
ing, and general edema improved and her body weight re-
covered from 68 kg to 63 kg at 3 weeks after rifampicin dis-
continuation, and a random urine protein-to-creatinine ratio 
was 0.14 at 8 weeks (Fig. 2). Furthermore, her serum albu-
min and cholesterol levels were shown to be 3.9 g/dL and 
Hg and her body temperature was 36.9°C. Physical exami-
nation was unremarkable, and urinalysis did not reveal any 
abnormal findings. Laboratory findings were as follows: he-
moglobin 11.7 g/dL, hematocrit 32.7%, blood urea nitrogen 
(BUN) 6.9 mg/dL, serum creatinine 0.74 mg/dL, sodium 
130 mEq/L, potassium 3.9 mEq/L, total protein 5.6 g/dL, al-
bumin 3.9 g/dL, and total cholesterol 167 mg/dL. According 
to chest X-ray, a pleural effusion was present in the left low-
er lobe. The pleural fluid (PF) was exudative, and PF analy-
sis showed a pH of 7.4, total protein of 5800 mg/dL, albu-
min of 3200 mg/dL, lactate dehydrogenase of 679 IU/L, 
and glucose of 92 mg/dL. In addition, the white blood cell 
(WBC) count was 3879/mm3 with 99% mononuclear cells, 
and adenosine deaminase (ADA) was shown to be 104.0 
IU/L in the PF. Pleural biopsy and pleural cytology were 
negative for malignancy. Based on the exudative character-
istics and the high ADA level in the PF, pleural tuberculosis 
was suspected and anti-tuberculosis treatment was started. 
Treatment comprised rifampicin 600 mg/day, isoniazid 300 
mg/day, ethambutol hydrochloride 1200 mg/day, and pyra-
zinamide 1500 mg/day.
During the 4-week anti-tuberculosis therapy regimen, the 
patient developed nausea, vomiting, general weakness, and 
edema. Urinalysis revealed 4+ proteinuria with a few tran-
sitional epithelial cells, some coarse granular casts, and 
many mucous threads. According to a 24-h urine collection, 
protein and albumin values were 9.2 and 6.2 g/day, respec-
tively. Laboratory findings were as follows: hemoglobin 
12.1 g/dL, WBC 5490/mm3, BUN 33.2 mg/dL, serum cre-
atinine 1.36 mg/dL, creatinine clearance 39 mL/min, total 
protein 5.6 g/dL, albumin 2.4 g/dL, serum aspartate amino-
transferase 282 IU/L, alanine aminotransferase 282 IU/L, 
normal total bilirubin, and a total cholesterol of 283 mg/dL. 
Fig. 1. (A) Light microscopy shows minor abnormalities of the glomeruli. The tubules show minimal atrophy and mild focal tubular injury. 
The interstitium is widened by minimal fibrosis. Non-sclerotic glomeruli are normocellular without mesangial expansion (H&E staining). 
(B) Electron microscopy shows diffusely effaced foot processes. The glomerular basement membranes are relatively even, but focal thin-
ning of the lamina densa is noted. The mesangium is not expanded and is free of electron-dense deposits (H&E staining).
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er medications except for daily 10 mg of amlodipine. We 
found out that heavy proteinuria developed after using anti-
tuberculosis agents. Fortunately, her proteinuria was im-
proved after discontinuation of rifampicin and isoniazid. In 
addition, we added isoniazid except for rifampicin, but MCD 
did not recur. Taken together, the use of rifampicin seems to 
have resulted in developing MCD mostly in this case.
Although there are no definite mechanisms offered for ri-
fampicin-induced MCD, a hypersensitivity mechanism has 
been suggested in many drug-induced MCD cases. For ex-
ample, drug exposure can result in the release of permselec-
tivity promoting factors from activated inflammatory or im-
mune cells, causing MCD.13 Another possible mechanism 
of MCD is via direct toxin effects on glomerular epithelial 
cells, resulting in abnormal permeability and effacement of 
the foot processes.13 Neugarten, et al.7 reported the first case 
of rifampicin-induced nephrotic syndrome, and described 
the patient as having acute interstitial nephritis with heavy 
proteinuria and effacement of the glomerular epithelial 
cells. They suggested that cell-mediated and humoral im-
mune responses to the rifampicin treatment could develop,7 
and Tada, et al.9 suggested that endothelial injury resulting 
from rifampicin-induced hemolysis and thrombocytopenia 
seems to play a role in the development of nephrotic syn-
drome.9 In our case, there was no electron-dense glomeru-
lar deposits or immune complex glomerulonephritis to sug-
gest a humoral immune mechanism.7 Additionally, there 
was no hemolysis or thrombocytopenia. Thus, we surmised 
that, rifampicin-induced MCD in this case, might have 
originated from direct toxin effects. 
In many cases, withdrawal of the offending drugs can lead 
to a full recovery, and glucocorticoids may hasten the return 
of renal function and ameliorate proteinuria.13 In one rifam-
picin-induced MCD case, the MCD was improved after oral 
administration of prednisolone and the cessation of rifampi-
cin.9 We simply terminated the rifampicin instead of initiat-
ing steroid therapy, and the patient recovered from heavy 
proteinuria, edema and hypoalbuminemia thereafter.
Although additional studies are required, simply discon-
tinuing rifampicin may improve the rifampicin-induced 
MCD without the need for steroid therapy.
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